PROVETOP

Biotinylated Human BTLA Protein

Catalog No: BTLA-HB003

Species
Human
Expression System
HEK293
Tag
His, Avi
Activity
Activity verified

Product overview

Recombinant Biotinylated Human BTLA Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Lys31-Ser150 (UniProt accession: Q7Z6A9-1).

Product Details

Molecular Aliases
CD272; BTLA; BTLA1; FLJ16065; MGC129743
Protein Length
Lys31-Ser150
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 16.7 kDa. Due to glycosylation, the protein migrates to 38-50 kDa based on Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE > 90% as determined by HPLC
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
State
Lyophilized
Storage Conditions
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Reconstitution Advice
Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.

Data Display

Bis-Tris PAGE
BTLA-HB003 Bis-Tris-PAGE-white result

Biotinylated Human BTLA on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC
BTLA-HB003 SEC-HPLC result

The purity of Biotinylated Human BTLA is greater than 95% as determined by SEC-HPLC

ELISA
BTLA-HB003 ELISA result

Immobilized Biotinylated Human BTLA, His Tag at 2μg/ml(100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Human HVEM, hFc Tag with the EC50 of 8.6ng/ml determined by ELISA (QC Test).

ELISA
BTLA-HB003 ELISA-2 result

Immobilized Anti-BTLA Antibody, hFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human BTLA, His Tag with the EC50 of 8.0ng/ml determined by ELISA.

Background

B- and T-lymphocyte attenuator (BTLA; CD272) is a 35 kDa type I transmembrane glycoprotein in the CD28 family of T cell costimulatory molecules. BTLA is a inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2. BTLA may interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14.

References

  1. Haymaker C L, Wu R C, Ritthipichai K, et al. BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties[J]. OncoImmunology, 2015, 4(8):e1014246. Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lyophilized powder.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support